Steve Blumenthal

Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY.

Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY.

Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY.

Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY.